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ABST RACT

Multiple myeloma (MM) is a plasma cell neoplasm, characterized
by periods of remission and relapses. The emergence of novel
therapies, with multiple mechanisms of action and fewer adverse
reactions, brings more and better options and also a higher survival
rate. However, MM is still an incurable disease, and patients
eventually become refractory to an extensive range of therapies. We
present the case of a patient diagnosed with MM standard risk, who
was at first refractory to multiple treatment regimens, and then had
an unexpected and stable complete response to a newer drug of the
same class.
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Introduction
Multiple myeloma (MM) is a plasma-cell neoplasm,
representing 10-13% of hematologic malignancies [1,2].
Although it is usually a chronic disorder, and many
therapies are available, it remains incurable. We present a
standard risk MM patient, who first was unexpectedly
refractory to multiple treatment regimens, and then had a
spectacular and stable response to a newer drug of a
previously used class.

Case Presentation
A 63-years-old male was admitted to our department
with fatigue and severe low back pain radiating to the lower
right extremity, non-related to trauma. His past medical
history was unremarkable, except for anemia discovered
one-year prior presentation. Physical examination was
normal, except for pallor. Laboratory analyses are
displayed in Table 1. Diagnosis was multiple myeloma IgG
lambda secretory, stage II. Also, he presented an L3vertebral tumor which was highly suggestive for
plasmacytoma.

After establishing the diagnosis, chemotherapy was
initiated with a melphalan-free regimen with the patient
eligible for autologous hematopoietic stem cell
transplantation (auto-HCT). We started CyBorD protocol
(cyclophosphamide, bortezomib, dexamethasone), without
significant complications. The L3 vertebral tumor was
excised. Postoperative histopathological exam confirmed
the plasmacytoma. Evaluation after four cycles showed
only partial response (Table 2).
We proceeded with hematopoietic stem cell collection
(apheresis from peripheral blood) – 5.17x106 CD34+
cells/kg, enough for two auto-HCTs. During
hospitalization, the patient developed femoral-popliteal
deep venous thrombosis, complicated with pulmonary
thromboembolism. He was started on anticoagulants, with
favorable evolution.
We continued with another four cycles of CyBorD,
without complications. Evaluation revealed stable disease
(Table 2), but far from an appropriate response. The
transplant team recommended continuing treatment as
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before, high-dose melphalan and auto-HCT, but because of
the unsatisfactory response, with another regimen.
As the patient did not fit the official reimbursement
criteria for thalidomide, and lenalidomide is not available
in Romania, the only available regimen was VAD
(vincristine, doxorubicin, dexamethasone), which
unfortunately was followed by grave complications: a
severe infection of the upper left limb, requiring surgical
intervention, broad-spectrum antibiotics, and a one-month
hospitalization; two weeks after discharge, he developed
bronchopneumonia with subsequent septic shock, and
paroxysmal atrial fibrillation, all requiring again a
prolonged hospitalization and intensive care. Also, reactive
depression appeared, necessitating antidepressants.
Table 1. Laboratory findings at diagnosis
Laboratory tests (normal
ranges)

Patients’ findings

Complete Blood count
White Blood Cells (3.610.2x109/L)

4.6x109/L

Hemoglobin (12.516.3g/dL)

9.1g/dL

Hematocrit (36.7-47.1%)

27.5%

Medium Cell Volume (73.096.2fL)

93.4fL

Platelet Count (152348x109/L)

292x109/L

Peripheral Blood Smear

rouleaux

Erythrocytes Sedimentation
Rate (5-10mm/h)

84mm/h

Meanwhile, the disease rapidly progressed and even the
weak response was lost (Table 2). Auto-HCT was delayed
due to lack of proper disease control, multiple and severe
infectious complications during chemotherapy, and also by
patients’ preference. He received three cycles of MP
(melphalan, prednisone) protocol.
A few months later, carfilzomib became available. We
decided to start Kd (carfilzomib, dexamethasone) protocol,
20 months after diagnosis. Evaluation after four cycles
showed very good partial response, and after six cycles, a
complete response (Table 2). Evolution under treatment
with Kd protocol was favorable. Currently, the patient is at
cycle 24, maintaining CR, and with no other complications
except for mild hematological toxicity.
Laboratory findings at diagnosis
Laboratory tests (normal
ranges)
Serum immunofixation test

IgG-λ monoclonal
protein

IgG (700-1600mg/dL)

2416.5mg/dL

Serum protein electrophoresis
Gamma-globulins (11-21%)

56.2%

A/G ratio (1.39-2.23)

0.45

Cytogenetic examination

del17p-

C-reactive protein (0-5mg/L)

1.36mg/L

Proteinuria/24 h

625.28mg/24 h

Bone marrow aspirate

38% plasma cell
infiltrate CD38+
CD138+ CD20CD117+

Whole body CT-scan

Multiple well-defined
lytic lesions,
predominantly
located in the
vertebral bodies and
in the pelvis

Magnetic Resonance Imaging

L3 vertebral tumor,
with intracanalicular
extension and severe
compression; diffuse
and focal alterations
in bone structure

Blood chemistry
Creatinine (0.5-1.5mg/dL)

1.1mg/dL

Serum calcium (8.210.7mg/dL)

9.44mg/dL

Serum total protein (6.28.5g/dL)

13.09g/dL

Albumin (3.4-5.2g/dL)

3.9g/dL

Beta2-microglobulin

5.05mg/L

Coagulation tests
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Table 2: Evolution of hematological parameters
Laboratory tests

Month 6

Month 9

Month 12

Month 25

Month 27

(4 CyBorD)

(+4 CyBorD)

(+1 VAD)

(+3 MP +4 Kd)

(+2 Kd)

Serum total protein

9.4g/dL

9.2g/dL

10.8g/dL

6.8g/dL

6.7g/dL

Gamma globulin

35.4%

34.4%

44.7%

19.4%

6.2%

IgG

3430mg/dL

4073mg/dL

6786mg/dL

1255mg/dL

883mg/dL

Serum immunofixation

positive

positive

positive

positive

negative

Proteinuria

negative

-

negative

negative

negative

Bone marrow plasma cells

-

2%

-

1%

undetectable

Discussions
Life expectancy in MM depends on the response to
therapy. It has increased in parallel with the emergence of
novel therapies with various mechanisms of action [1,3,4].
The clinical evolution of MM, as with other
lymphoproliferative disorders [5,6,7] is marked by periods
of remission and relapse, the latter becoming more frequent
and more aggressive with each regimen [1,4]. Despite the
multiple options available, MM is still incurable, and
patients ultimately become refractory to a broad spectrum
of drugs [1].
Proteasome inhibitors are an effective treatment of MM
[8]. Here, we used a bortezomib-based regimen as firstline, approved for transplant eligible patients. Our patient
first had only an insufficient partial response, and later
became refractory – aggressive MM although the initial
prognosis markers were not unfavorable (standard risk,
stage II). Since no other options were available at the time,
we chose VAD regimen. We administered only one cycle
when severe, life-threatening infectious complications
appeared (after a less intensive protocol than the previous
one). We decided to use a regimen with lower toxicity,
melphalan-based, as stem cells were already collected. No
response was observed after any of those regimens. When
carfilzomib became available, though the patient had a
refractory disease with a high and progressive burden and
multiple previous complications, we decided to continue
treatment with Kd regimen. The response was extremely
favorable and mostly unexpected: stable CR and no
adverse reactions whatsoever.
It is known that carfilzomib has greater selectivity and
irreversibly inhibits the proteasome, and thus responses
may appear even in bortezomib-refractory patients [8].

However, median progression free survival (PFS) for Kd
regimen in bortezomib-exposed patients with 2-3 previous
treatment lines, is 13.1months [9]. Our patient already has
a double PFS and maintains response. Also, CR rates
reported for Kd combination even in standard risk patients
are actually quite low (13.0%) [10].
So, after the unexpected inadequate first response, our
patient surprised us again with such a favorable outcome:
CR and prolonged PFS at Kd, without notable adverse
reactions, in a patient treated with three lines and previous
severe complications.

Highlights
✓ Unexpected favorable and durable response to a newer
drug of the same class that was inefficient as first line,
in a patient who had become refractory provides
renewed hope for the patient, as newer and more
effective drugs are constantly being developed.

Conclusions
We aim to illustrate hereby the case of a patient who
did not have an unfavorable prognosis at diagnosis by
using the known markers, and yet responded poorly and
progressed under standard therapy. But, he had the chance
to benefit from a newer drug, although from the same class
as the one to which he had already showed resistance.
Nevertheless, he showed an unexpected complete and
stable response, beyond what statistics might have
predicted.
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